Written and maintained by CASRAI Editorial Board
Published
On this page
Prostate cancer risk stratification is the standardized clinicopathologic classification system used in urology, medical oncology, and radiation oncology to estimate the probability of biochemical recurrence, metastasis, and prostate-cancer-specific mortality in patients with newly diagnosed, clinically localized or locally advanced adenocarcinoma of the prostate. Codified by the National Comprehensive Cancer Network (NCCN) and the American Urological Association / American Society for Radiation Oncology (AUA/ASTRO), risk stratification integrates three foundational variables—pre-treatment serum PSA, ISUP Grade Group (Gleason score), and AJCC clinical T stage—alongside biopsy core volume to determine whether a patient is managed with active surveillance, monotherapy, or multimodal therapy.
What Is Prostate Cancer Risk Stratification?
Originally pioneered by Anthony V. D’Amico, MD, PhD, in 1998 as a three-tier model (Low, Intermediate, and High Risk), modern clinical risk stratification subdivides localized and locally advanced prostate cancer (clinically node-negative cN0 and metastasis-negative cM0) into six prognostic tiers by incorporating the 2014 International Society of Urological Pathology (ISUP) 5-tier Grade Group system (Epstein et al., 2016) and biopsy core involvement:
- ISUP Grade Group 1 (Gleason Score ≤ 6; 3+3=6): Only individual discrete well-formed glands; very low metastatic potential.
- ISUP Grade Group 2 (Gleason Score 3+4=7): Predominantly well-formed glands with a lesser component of poorly formed/fused/cribriform glands.
- ISUP Grade Group 3 (Gleason Score 4+3=7): Predominantly poorly formed/fused/cribriform glands with a lesser component of well-formed glands (carries significantly higher recurrence risk than 3+4=7, driving the split between Favorable and Unfavorable Intermediate risk).
- ISUP Grade Group 4 (Gleason Score 8; 4+4, 3+5, or 5+3): Only poorly formed/fused/cribriform glands, or predominantly well-formed glands with a lesser component lacking glands.
- ISUP Grade Group 5 (Gleason Score 9–10; 4+5, 5+4, or 5+5): Lack of gland formation (or with necrosis) with or without poorly formed/fused/cribriform glands.
NCCN and AUA/ASTRO Prostate Cancer Risk Stratification Matrix
Both the NCCN Guidelines (NCCN Prostate Cancer Guidelines) and the AUA/ASTRO Clinically Localized Prostate Cancer Guideline (AUA/ASTRO Guideline) stratify patients into the following six risk groups:
| Risk Group Tier | Clinical T Stage (AJCC) | ISUP Grade Group (Gleason) | Serum PSA (ng/mL) | Additional Biopsy Core & PSA Density Criteria |
|---|---|---|---|---|
| Very Low Risk | cT1c |
Grade Group 1 (≤ 6) | PSA < 10 | All of: < 3 positive biopsy cores, ≤ 50% cancer in any core, and PSA density < 0.15 ng/mL/g |
| Low Risk | cT1a–cT2a |
Grade Group 1 (≤ 6) | PSA < 10 | Does not qualify for Very Low Risk (e.g., ≥ 3 positive cores or PSA density ≥ 0.15 ng/mL/g) |
| Favorable Intermediate Risk | cT2b–cT2c (Intermediate factor) |
Grade Group 1 or 2 (3+4=7) | PSA 10–20 (Intermediate factor) | All of: Has only 1 Intermediate Risk Factor (IRF: cT2b–cT2c, Grade Group 2–3, or PSA 10–20), Grade Group 1 or 2, and < 50% of biopsy cores positive |
| Unfavorable Intermediate Risk | cT2b–cT2c |
Grade Group 2 or Grade Group 3 (4+3=7) | PSA 10–20 | Any of: 2 or 3 IRFs, Grade Group 3, or ≥ 50% of biopsy cores positive |
| High Risk | cT3a |
Grade Group 4 or 5 (Gleason 8–10) | PSA > 20 | Has only 1 High-Risk feature (cT3a, Grade Group 4–5, or PSA > 20) and no Very High Risk features |
| Very High Risk | cT3b–cT4 |
Primary Gleason Pattern 5 (e.g., 5+4 or 5+5) | Any PSA | Any of: cT3b (seminal vesicle invasion) or cT4, primary Gleason pattern 5, 2 or 3 High-Risk features, or > 4 cores with Grade Group 4 or 5 |
How Is Prostate Cancer Risk Stratification Used in Clinical Research and Healthcare?
In multidisciplinary genitourinary oncology clinics and randomized clinical trials, the assigned risk tier directly governs staging imaging, germline/genomic biomarker testing, and treatment selection:
- Active Surveillance vs. Definitive Therapy: For Very Low and Low Risk patients (and selected Favorable Intermediate Risk patients with low-volume Grade Group 2 disease), NCCN and AUA/ASTRO guidelines recommend Active Surveillance (serial PSA testing, digital rectal examination, multiparametric MRI [mpMRI], and confirmatory biopsy) to avoid overtreatment morbidity.
- Short-Term vs. Long-Term Androgen Deprivation Therapy (ADT): When patients choose external beam radiation therapy (EBRT), Favorable Intermediate Risk disease is treated with radiation monotherapy, whereas Unfavorable Intermediate Risk requires adding 4 to 6 months of short-term ADT, and High / Very High Risk disease requires 18 to 36 months of long-term ADT (with abiraterone added in selected Very High Risk protocols) or radical prostatectomy with pelvic lymph node dissection (PLND).
- Staging Imaging (PSMA PET/CT) & Genomic Classifiers: Metastatic staging imaging (such as
68Ga-PSMA-11or18F-DCFPyLPSMA PET/CT, or conventional CT/bone scan) is indicated starting at Unfavorable Intermediate, High, and Very High Risk. Tissue-based gene expression classifiers (such as the 22-gene Decipher genomic prostate score, Prolaris, or Oncotype DX GPS) and histopathology AI biomarkers refine prognostic sub-stratification for borderline surveillance or ADT intensification decisions, and serve as mandatory randomization strata in cooperative group oncology trials (NRG Oncology, SWOG, Alliance).
Frequently Asked Questions
What is prostate cancer risk stratification?
Prostate cancer risk stratification is the clinical staging and prognostic framework defined by NCCN and AUA/ASTRO guidelines that classifies localized and locally advanced prostate cancer into six tiers—Very Low, Low, Favorable Intermediate, Unfavorable Intermediate, High, and Very High Risk—based on serum PSA level, ISUP Grade Group (1–5), clinical T stage (cT1–cT4), and percentage of positive biopsy cores.
How is prostate cancer risk stratification used in clinical research and healthcare?
In clinical oncology and urology, risk stratification determines whether a patient should undergo active surveillance (Very Low/Low risk), radiation or prostatectomy alone (Favorable Intermediate), radiation with 4–6 months of hormone therapy (Unfavorable Intermediate), or multimodal therapy with PSMA PET staging and 18–36 months of androgen deprivation therapy (High/Very High risk), while serving as the primary eligibility and randomization criterion in prostate cancer clinical trials.







